Founded by Kathy Giusti, a myeloma patient and Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation, the mission of the MMRF is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia. The MMRC is led by an exceptional Leadership Team, including a full scientific and clinical staff, which is headquartered in Norwalk, Conn.

The MMRC is currently comprised of sixteen world-renowned academic institutions: Baylor Charles A. Sammons Cancer Center at Dallas, Barbara Ann Karmanos Cancer Institute, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, The John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Mount Sinai School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University in St. Louis .

Integral to MMRC research and drug development efforts is the MMRC Tissue Bank, a cutting-edge resource that provides a “bridge” between laboratory and clinical research conducted by the MMRC. The MMRC Tissue Bank also plays a vital role in the MMRC’s pre-clinical validation studies of novel and combination therapies and in conducting basic science research to develop a greater understanding of the biology of the multiple myeloma.

The MMRC is currently conducting exciting research efforts across through three highly aligned Research Cores: Genomics, Validation, and Clinical Trials. These efforts truly span the spectrum of drug development - from the identification of new druggable targets, to the validation of novel and combination therapies, to advancing new compounds into Phase I and II clinical trials.

Committed to bringing better, more effective new treatments to patients as quickly as possible, the MMRC is highly focused on spearheading Phase I and II clinical trials with associated correlative science studies. Since its inception, the MMRC has faciliated the launch of 30 clinical trials of novel compounds and combination approaches. The MMRC also conducts pre-clinical validation studies to identify and prioritize the most promising novel compounds and combination therapies, and conducts genomics studies to develop a greater understanding of the biology of the multiple myeloma.